Published: 16 March 2022
Archived: 21 August 2024

About Medsafe

COVID-19 Archive

Adverse events following immunisation with COVID-19 vaccines: Safety Report #41 – 28 February 2022

Medsafe advises people NOT to make any decisions about vaccination based on information contained in this report. If you have questions or concerns about receiving a vaccine, please speak to a health care professional.

• What you need to know
• Introduction
• Adverse events following immunisation (AEFI) reported
• Summary of reported deaths
• Observed versus expected analyses
• Adverse events of special interest
• Summary of safety signals
• Definitions
• More information

What you need to know – up to and including 28 February 2022

This report now includes data for the AstraZeneca vaccine. Note that counts may change due to receipt of additional information.

For the Comirnaty (Pfizer) vaccine

For the AstraZeneca vaccine

• The protective benefits of vaccination against COVID-19 far outweigh the potential risks of vaccination.
• The Ministry of Health, Medsafe, the Centre for Adverse Reactions Monitoring and manufacturers continue to closely monitor the safety of COVID-19 vaccines. We’ll respond to any safety issues right away and will inform New Zealanders about any risks that arise in New Zealand.
• For more information about Covid Vaccine Immunisation Programme, please go to Unite against COVID-19 or call Healthline 0800 611 116 to talk to someone about your concerns.
• Comirnaty: There were 6,013 non-serious and 395 serious reports since the last update. Sadly, we had 9 more notifications of death. Any possibility of a causal link is investigated as part of our routine investigations and no new safety concerns with the Comirnaty vaccine were raised by these reports. For information about reported deaths, please refer to the summary of reported deaths.
• AstraZeneca: The vaccine became available on 26 November 2021. Up to 28 February 2022, there have 247 non-serious and 17 serious reports for the AstraZeneca vaccine. There have been no notifications of death.
• Comirnaty: Up to 28 February 2022 a total of 10,621,074 doses of Comirnaty have been administered and 58,135 AEFIs were reported. This means that more than 10.5 million doses of Comirnaty were administered that did not result in a report of an adverse event. On average for every 10,000 people who are vaccinated 55 people report an AEFI. It is also important to keep in mind that a report can be submitted for any cause and is not necessarily associated with the vaccine.
• AstraZeneca: Up to 28 February 2022, a total of 8,003 doses of AstraZeneca vaccine have been administered and 264 AEFIs were reported. This means that more than 7,700 doses of AstraZeneca vaccine were administered that did not result in a report of an adverse event. On average for every 10,000 people who are vaccinated 330 people report an AEFI. It is also important to keep in mind that a report can be submitted for any cause and is not necessarily associated with the vaccine.
• The next safety report (#42) will be published on 13 April 2022, for the period ending 31 March 2022.

Introduction

The national roll-out of COVID-19 vaccines commenced on 20 February 2021 with Pfizer-BioNTech (Comirnaty). The AstraZeneca vaccine became available on 26 November 2021.

This page provides information on the number of adverse events following immunisation (AEFI) reports received for COVID-19 vaccines.

An AEFI is an untoward medical event which follows immunisation and does not necessarily have a causal relationship with the administration of the vaccine. The adverse event may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.

All medicines can cause side effects, the known side effects for COVID-19 vaccines are listed in the data sheets and consumer medicine information (CMI).

Search for a data sheet or CMI

Suspected AEFI to COVID-19 vaccines are reported to the Centre for Adverse Reactions Monitoring (CARM). The Ministry of Health (through Medsafe) contracts the collection of this information to CARM, based at the University of Otago in Dunedin. Medsafe is closely monitoring the AEFI reported from the use of the COVID-19 vaccine. Find out more about vaccine safety monitoring.

Medsafe and CARM thank everyone who has contributed to the monitoring of COVID-19 vaccines. Please continue to report any adverse events following immunisation.

Adverse events following immunisation (AEFI) reported

The information below includes:

• AEFI reports by prioritised ethnicity and vaccine dose
• AEFI reports by age band and vaccine dose
• the top 10 most frequently reported AEFIs by vaccine dose
• reported AEFIs by reporter type.

Table 1: AEFI reports received by prioritised ethnicity and vaccine dose, by vaccine, up to and including 28 February 2022

Ethnicitya	Comirnaty				AstraZeneca
	Dose 1	Dose 2	Dose 3	Total	Total
Māori	2,544	1,943	677	5,164	27
Pacific Peoples	764	698	213	1,675	3
Asian	2,670	2,111	980	5,761	12
European or other	20,392	16,892	7,266	44,550	221
Unknownb	515	351	102	968	1
Total	26,885	21,995	9,238	58,118c	264d

Notes:

1. The prioritised ethnicity classification system allocates each person to a single ethnic group, based on the ethnic groups they identify with. Where people identify with more than one group, they are assigned in this order of priority: Māori, Pacific Peoples, Asian, and European/Other. So, if a person identifies as being Māori and New Zealand European, the person is counted as Māori. See Ethnicity Data Protocols for further information.
2. There were 968 Comirnaty and 1 AstraZeneca AEFI reports where the person’s ethnicity was not reported. Counts may change due to receipt of additional information. Ethnicity is not required for an AEFI report to be considered valid. See ‘Valid report’ in the Definitions section below.
3. The total is different from the cumulative total above because it excludes 17 AEFI reports received for infants who did not receive the vaccine.
4. Due to the low numbers of reports to date, only totals for AstraZeneca are shown to protect privacy.

Table 2: AEFI reports received by age band and vaccine dose, by vaccine, up to and including 28 February 2022

Age	Comirnaty				AstraZeneca
	Dose 1	Dose 2	Dose 3	Total	Total
5 - 11 years	552	<6	0	557	0
12 - 19 years	2,800	1,683	175	4,658	8
20 - 29 years	5,262	3,940	1,608	10,810	39
30 - 39 years	5,871	4,869	2,099	12,839	59
40 - 49 years	4,576	4,215	1,933	10,724	69
50 - 59 years	3,860	3,558	1,694	9,112	60
60 - 69 years	2,334	2,144	1,040	5,518	22
70 - 79 years	1,115	1,092	497	2,704	6
80+ years	473	461	184	1,118	1
Unknowna	42	28	8	78	0
Total	26,885	21,995	9,238	58,118b	264c

Notes:

1. There were 78 Comirnaty AEFI reports where the person’s age was not reported. Counts may change due to receipt of additional information. Age is not required for an AEFI report to be considered valid. See ‘Valid report’ in the Definitions section below.
2. The total is different from the cumulative total above because it excludes 17 AEFI reports received for infants who did not receive the vaccine.
3. Due to the low numbers of reports to date, only totals for AstraZeneca are shown to protect privacy.

Figure 1: Top 10 most frequently reported AEFIs for the Comirnaty vaccine, by dose, up to and including 28 February 2022

Figure 2: Top 10 most frequently reported AEFIs for the AstraZeneca vaccine, any dose, up to and including 28 February 2022

Download a list of the top 50 most frequently reported AEFIs (any dose)..

Table 5: Reported AEFIs by reporter type (any vaccine) up to and including 28 February 2022

Reporter type	Number of reportsa
Public Patient	24,567
CIR Vaccinator	14,458
Nurse	8,172
Other	4,746
General Practitioner	7,016
Public: On behalf of a patient	2,005
Pharmacist	357
Not specified	112

1. The total number here differs from the total reported cases elsewhere because a single case can contain multiple reports from different sources.

Please note that one adverse event report, which represents one person, may report on more than one symptom. Reports are sent to CARM if the reporter suspects that the vaccine may have caused the event. This does not necessarily mean that the vaccine did cause the event.

The number of reports can be influenced by how many people are being vaccinated, media attention, the nature of the events (eg, how painful the vaccination was), and other factors which vary over time. Not everyone who has an adverse reaction reports it, and some people may report AEFIs after each vaccination. The information here shows the number of reports not the number of people who experienced an AEFI.

The information is limited by the information provided in the report and may change over time due to quality control procedures and/or receipt of additional information. Non-valid reports are not included in the data.

Summary of reported deaths

Up to and including 28 February 2022, a total of 156 deaths were reported to CARM after the administration of the Comirnaty vaccine. Following medical assessments by CARM and Medsafe it has been determined that:

• 89 of these deaths are unlikely related to the COVID-19 vaccine
• 51 deaths could not be assessed due to insufficient information
• 14 cases are still under investigation.
• 2 deaths were likely due to vaccine induced myocarditis (awaiting Coroner’s determination)

By chance, some people will experience new illnesses or die from a pre-existing condition shortly after vaccination, especially if they are elderly. Therefore, part of our review process includes comparing natural death rates to observed death rates following vaccination, to determine if there are any specific trends or patterns that might indicate a vaccine safety concern. See below for more information about these observed-versus-expected analyses.

To date, the observed number of deaths reported after vaccination is actually less than the expected number of natural deaths.

There have been no deaths reported for the AstraZeneca vaccine.

Table 6: Mortalities by age group up to and including 28 February 2022 reported to CARM

Age	Mortalitiesa
10 - 29 years	8
30 - 59 years	31
60 - 79 years	71
80+ years	46

1. Counts may change due to receipt of additional information, for example, identification of duplicate reports.

Observed-versus-expected analyses – Comirnaty vaccine

It is important to note that no conclusions should be made from these observed-versus-expected analyses in isolation. Other investigations looking at pre-existing risk factors are always required.

The analyses below show that the number of deaths recorded in the mortality register for people vaccinated with the Comirnaty vaccine is lower than expected based on the average number of deaths in previous years over the same number of days (natural death rate).

For these observed-versus-expected analyses, we compare the vaccinated population to natural (expected) rates (taken from past data). The comparison is done by dividing the observed rate of death in the vaccinated population by the expected rate to give the relative risk (RR).

Observed / Expected Rate = Relative Risk (RR)

The methods used to calculate the relative risk also provide a confidence interval (CI). The confidence interval is a range of values that we are fairly sure our true value lies in. We are using a 95 percent confidence interval (95% CI), which is the range that will include the true value 95 percent of the time. If both the relative risk AND the lower end of the confidence interval are greater than one (>1.0), this is statistically significant and could indicate an increased risk of death in the vaccinated population. This will be highlighted in the table when applicable.

We are monitoring people for 21 days after vaccination. This monitoring period was chosen because people can receive their second dose a minimum of 21 days after the first dose. Age-specific natural (expected) death rates were obtained for the period 2008–2019. One reason for the number of deaths in the vaccinated group appearing to be lower could be that healthcare professional of extremely frail patients give the advice not to get vaccinated.

These analyses do not consider causality and instead, report on all deaths that have occurred in the monitoring period (observed deaths). This results in a much higher number than those reported to CARM where the reporter (eg, family member or health care provider) might have had a suspicion the vaccine could have played a role. The number of observed deaths also includes deaths from other causes, such as deaths due to accidents, medical conditions, other medicines or medical treatments.

Please note that the mortality collections operate many weeks in arrears. This means that these observed-versus-expected analyses will only be updated once a month and will also be in arrears – for example, the tables below are for the period up to 31 December 2021.

Table 7: Observed-versus-expected deaths^a by age group from any cause, up to 21 days after Comirnaty dose 1, 19 February 2021 to 31 December 2021

Age	Dose 1 – number administered	Expected deathsb in monitoring period	Observed deathsc in monitoring period	Relative riskc (95% confidence interval)
12 to 19	478,560	8.9	11	1.24d [0.62 – 2.21]
20 to 29	635,863	22.1	21	0.95 [0.59 – 1.45]
30 to 39	664,906	30.5	14	0.46 [0.25 – 0.77]
40 to 49	586,478	56.8	23	0.40 [0.26 – 0.61]
50 to 59	603,635	134.7	61	0.45 [0.35 – 0.58]
60 to 69	514,136	269.2	120	0.45 [0.37 – 0.53]
70 to 79	348,213	495.0	237	0.48 [0.42 – 0.54]
80+	182,091	1,080.5	592	0.55 [0.50 – 0.59]
Total	4,013,882	2,097.7	1,079	0.51 [0.48 – 0.55]

1. Expected and observed deaths among people who have received dose 1 of the Pfizer/BioNTech vaccine during the specified period, by age group. Inclusion criteria were: monitoring time of 21 days after receiving dose 1, all genders, all ethnicities, aged 12 years and older. The data was collected from the Mortality database.
2. Data for expected death rates was obtained from the AESI background rate (SAFE) study provided by the University of Auckland. The age-specific background rates used are the average from 2008-2019.
3. The observed deaths column (4th column) is a raw data observation, and this is used to calculate the relative risk (5th column).
4. The relative risk of 1.24 does not indicate there is an increased risk of mortality in this age group because the lower end of the confidence interval is 0.62 (ie, <1.0). The COVID-19 Independent Safety Monitoring Board (CV-ISMB) has reviewed AEFIs in children and found that this group was not disproportionately affected by the vaccine. Medsafe will continue to monitor this closely.

Table 8: Observed-versus-expected deaths^a by age group from any cause, up to 21 days after Comirnaty dose 2, 19 February 2021 to 31 December 2021

Age	Dose 2 – number administered	Expected deathsb in monitoring period	Observed deathsc in monitoring period	Relative riskc (95% confidence interval)
12 to 19	445,096	8.1	8	0.99 [0.43 – 1.94]
20 to 29	607,711	20.7	5	0.24 [0.08 – 0.56]
30 to 39	642,025	29.1	12	0.41 [0.21 – 0.72]
40 to 49	571,406	54.9	28	0.51 [0.34 – 0.74]
50 to 59	593,484	131.6	78	0.59 [0.47 – 0.74]
60 to 69	510,101	266.2	146	0.55 [0.46 – 0.65]
70 to 79	347,008	492.3	207	0.42 [0.37 – 0.48]
80+	180,942	1,071.5	606	0.57 [0.52 – 0.61]
Total	3,897,773	2,074.5	1,090	0.53 [0.49 – 0.56]

1. Expected and observed deaths among people who have received dose 2 of the Pfizer/BioNTech vaccine during the specified period, by age group. Inclusion criteria were: monitoring time of 21 days after receiving dose 2, all genders, all ethnicities, aged 12 years and older. The data was collected from the Mortality database.
2. Data for expected death rates was obtained from the AESI background rate (SAFE) study provided by the University of Auckland. The age-specific background rates used are the average from 2008-2019.
3. The observed deaths column is a raw data observation, and this is used to calculate the relative risk (5th column). Some cells could not be calculated because the numbers were too low (<6).

For further reading about the methodology used to analyse death rates, see:

• Centers for Disease Control and Prevention (CDC) – Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink. URL: https://www.cdc.gov/vaccinesafety/pdf/VSD-1342-COVID19-RCA-Protocol_FinalV1.1_508.pdf
• Kulldorff M, Davis RL, Kolczak M, et al. A maximised sequential probability ratio test for drug and vaccine safety surveillance. Sequential Analysis 30(1): 58–78. URL: https://www.tandfonline.com/doi/full/10.1080/07474946.2011.539924.

Adverse events of special interest

Adverse events of special interest (AESI) are pre-specified medically significant events that have the potential to be causally associated with the vaccine and must be carefully monitored. AESI can be serious or non-serious and can include:

• Events of interest due to their association with COVID-19 infection
• Events of interest for vaccines in general (eg, to the specific vaccine type or adjuvants).

The list of AESIs below takes into consideration the lists of AESIs from expert groups such as the Brighton Collaboration, manufacturers and other regulatory authorities. The AESI list changes based on the evolving safety profile of vaccines. It is important to note that although these adverse events may occur after being vaccinated with a COVID-19 vaccine in New Zealand, they are rare and may not necessarily be related to the vaccine. Medsafe and CARM review the reports to determine whether the vaccine may have played a role in the occurrence of these events.

Table 9: Adverse events of special interest (AESI) up to and including 28 February 2022

AESI Category	AESI	Comirnaty totala	AstraZeneca totala	Background rate (hospitalisations per year)b
Immune system disorders	Guillain-Barré Syndrome	26	0	273
	Thrombocytopenia	37	0	4,325
	Thrombosis with thrombocytopenia syndrome (TTS)	n/ac	0
	Anaphylaxisd	375	6	1,102
Cardiovascular system	Myocardial infarction (heart attack)	76	0	16,347
	Myocarditis/pericarditis	673	<6	931
Blood and lymphatic system	Thrombosis	54	0	2,863
	Embolism	132	<6	4,571
	Deep vein thrombosis (DVT)	115	0	519
	Vasculitis	73	0	4,325
	Haemorrhagee	150	0
Hepato-gastrointestinal and renal system	Acute kidney injury	23	0	38,631
	Acute liver injury	<6	0	420
	Pancreatitis	13	0	6,137
	Appendicitis	21	0	3,359
Nervous system	Aseptic meningitis	<6	0	744
	Encephalitis	9	0	409
	Stroke	108	0	14,776
	Bell's Palsy/facial paralysis	205	<6	694
	Myelitis/myelitis transverse	6	0	53
Infections and musculoskeletal	Erythema multiforme	16	0	97
	Arthritis	104	0	178
	Herpes zoster	344	<6	1,148
Pregnancy, puerperium and perinatal conditions	Abortion (spontaneous abortion /miscarriage)	62	0	290

1. Includes all AESI reports, both serious and non-serious. Counts below 6 are reported as <6 for privacy reasons. Counts may change due to receipt of additional information and subsequent reclassification of cases.
2. AESI background hospitalisation rates used to estimate the expected number of events in the general population, which help in vaccine safety surveillance. Counts indicate average of hospitalisation rates for the calendar years 2016-2019.
3. The thrombosis with thrombocytopenia syndrome (TTS) AESI occurs only in non-replicating viral vaccines (eg, the AstraZeneca vaccine)
4. Includes anaphylaxis reports meeting levels 1-3 of the Brighton Collaboration case definition.
5. Haemorrhage can manifest in different ways depending on the mechanism and anatomic location. It is difficult to know if the haemorrhage was minor or significant through the hospitalisation background rates.

Further information on Myocarditis and Pericarditis

Myocarditis is inflammation of the heart muscle, while pericarditis is inflammation of the tissue forming a sac around the heart. Myo-pericarditis means that both the heart muscle and the sac are inflamed.

There are many possible causes of myocarditis, the most common being viral infection. New Zealand data from the Global Vaccine Data Network indicates that the background rate of non-infective myocarditis (pre COVID-19) in the overall population from 2011 to 2019 was 1.81 per 100,000 person-years.

Up to 1 March 2022, the Centre for Adverse Reactions Monitoring (CARM) has received 360 spontaneous reports of myocarditis, pericarditis or myopericarditis where the report contained evidence of a clinical diagnosis and the symptom onset time was within 30 days of vaccination (to reduce the risk of including coincidental cases). These reports do not necessarily have a causal relationship with administration of Comirnaty and may represent coincidental events. The age ranges, by dose number, are shown in Figure 3. The time to onset of symptoms, by dose number, is shown in Figure 4. Of the 360 reports, 63 percent were for males and 38 percent reported that the myocarditis/pericarditis was experienced after dose one.

Figure 3: Ages of people reported with myocarditis/pericarditis after Comirnaty vaccination in New Zealand, by dose number, up to 1 March 2022

Figure 4: Time to onset of symptoms of myocarditis/pericarditis after Comirnaty vaccination in New Zealand, by dose number, up to 1 March 2022

Summary of safety signals

Persisting disability following Comirnaty vaccination

Medsafe and the COVID-19 Independent Safety Monitoring Board (CV-ISMB) has reviewed AEFI reports and the medical literature pertaining to persisting disability following vaccination. The Board was reassured by the data shown and felt it was in line with their clinical experience of individuals developing conditions with no clear diagnosis or cause. Medsafe will continue to monitor reports of this nature through routine pharmacovigilance.

Table 12: Summary of Medsafe’s investigations into possible safety signals

Safety signal	Outcome
Comirnaty vaccine
Blood clots	Continue to monitor. See also the Monitoring communication
Appendicitis	Continue to monitor
Myocarditis/pericarditis	Information has been added to Comirnaty data sheet. See also the Alert communication. Medsafe will continue to monitor this closely.
Herpes zoster	Continue to monitor
Bell’s palsy/facial paralysis	Continue to monitor
Menstrual disorder	Continue to monitor. See also the monitoring communication.
Stroke	Continue to monitor
Tinnitus	Continue to monitor
AEFIs in the elderly	Continue to monitor and updated data sheet
Pancreatitis	Continue to monitor
Glomerular diseases	Continue to monitor
Guillain-Barré Syndrome	Continue to monitor
Thrombocytopenia	Continue to monitor
AEFIs in children	Continue to monitor
Erythema multiforme	Continue to monitor
Pregnancy	Continue to monitor. See also the monitoring communication.
Persisting disability	Continue to monitor
AstraZeneca vaccine
Overview of AEFI reports to date	No safety signals identified

Definitions

Adverse event following immunisation (AEFI)

An AEFI is an untoward medical event which follows immunisation and does not necessarily have a causal relationship with the administration of the vaccine. The adverse event may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.

Serious adverse event following immunisation

An AEFI is considered serious if it:

• is a medically important event or reaction
• requires hospitalisation or prolongs an existing hospitalisation
• causes persistent or significant disability or incapacity
• is life threatening
• causes a congenital anomaly/birth defect
• results in death.

It is possible for different people to have experienced the same event but for the report to be serious for one person and non-serious for another person.

Adverse events of special interest (AESI)

An AESI is a pre-specified medically significant event that has the potential to be causally associated with the vaccine product based on past experience, the technology used to make the vaccine or the infection the vaccine is used to protect against. AESIs need to be carefully monitored and any potential association to vaccination confirmed by further analysis and studies.

Safety signal

Information on a new or known adverse event that may be caused by the vaccine and requires further investigation. Safety signals can be detected from a wide range of sources such as CARM reports, clinical studies and scientific literature.

Valid report

There are only four requirements for a valid AEFI report:

1. one patient identifier (eg, name, initials, gender, date of birth, age)
2. suspect medicine(s)
3. suspected reaction(s)
4. reporter details.

These four requirements are the minimum requirements. However, including more information in the report helps Medsafe to investigate the reaction more quickly. Reporting is easiest online.

More information

See the data sheets and consumer medicine information for the expected reactions for approved COVID-19 vaccines.

COVID-19 Vaccine Safety Monitoring Process

View Ministry of Health COVID-19 vaccine data

Latest listing of all cases received

The latest listing of AEFIs received is included in the attached spreadsheet. Medsafe advises patients NOT to make any decisions about vaccination based on information contained here.

Download AEFI-line-listing.xlsm